Objective. To provide the efficacy and safety of Multi-Gyn ActiGel used in the combination therapy and prevention in patients with recurrent bacterial vaginosis. Subjects and methods. Medical history data were collected and physical examination was carried out in 30 reproductive-aged patients with recurrent bacterial vaginosis. The diagnosis was based on Amsel’s criteria: a) assessment of the nature of vaginal discharge; b) determination of vaginal pH; c) use of amino test; d) microscopic examination of vaginal contents for key cells. Multi-Gyn ActiGel in combination therapy for bacterial vaginosis was prescribed to all the 30 patients according to the scheme: 20 ml (a daily dose of 4 ml, 2 ml twice a day, for 5 days), 10 applications. All the patients also received metronidazole 500 mg orally 2 times daily on the first day for 7 days according to the federal clinical guidelines for the management of patients with bacterial vaginosis (Moscow, 2015). A control group consisted of 10 women with bacterial vaginosis who received only metronidazole 500 mg orally twice daily for 7 days according to the same clinical guidelines. Recovery was established 14 days and 1 month after completion of treatment. Quality of life was assessed in all the patients with bacterial vaginosis before and after treatment with Multi-Gyn actiGel. Results. The use of Multi-Gyn actiGel in the combination treatment of patients with recurrent bacterial vaginosis was found to promote rapid recovery of vaginal microbiota, regression of clinical manifestations and to have a highly effective preventive effect in reducing the number of recurrences and increasing the duration of an inter-recurrence period. Conclusion. The study suggests that Multi-Gyn ActiGel is effective and safe in treating patients with recurrent bacterial vaginosis and that its use is feasible in obstetric/gynecologic practice.